Search

Your search keyword '"Chi, Susan N."' showing total 307 results
Start Over Author "Chi, Susan N." Publication Year Range Last 50 years
307 results on '"Chi, Susan N."'

2. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

Author

Kilburn, Lindsay B., Khuong-Quang, Dong-Anh, Hansford, Jordan R., Landi, Daniel, van der Lugt, Jasper, Leary, Sarah E. S., Driever, Pablo Hernáiz, Bailey, Simon, Perreault, Sébastien, McCowage, Geoffrey, Waanders, Angela J., Ziegler, David S., Witt, Olaf, Baxter, Patricia A., Kang, Hyoung Jin, Hassall, Timothy E., Han, Jung Woo, Hargrave, Darren, Franson, Andrea T., Yalon Oren, Michal, Toledano, Helen, Larouche, Valérie, Kline, Cassie, Abdelbaki, Mohamed S., Jabado, Nada, Gottardo, Nicholas G., Gerber, Nicolas U., Whipple, Nicholas S., Segal, Devorah, Chi, Susan N., Oren, Liat, Tan, Enrica E. K., Mueller, Sabine, Cornelio, Izzy, McLeod, Lisa, Zhao, Xin, Walter, Ashley, Da Costa, Daniel, Manley, Peter, Blackman, Samuel C., Packer, Roger J., and Nysom, Karsten

Published
2024
Full Text
View/download PDF

3. Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

Author

Kilburn, Lindsay B., Khuong-Quang, Dong-Anh, Hansford, Jordan R., Landi, Daniel, van der Lugt, Jasper, Leary, Sarah E. S., Driever, Pablo Hernáiz, Bailey, Simon, Perreault, Sébastien, McCowage, Geoffrey, Waanders, Angela J., Ziegler, David S., Witt, Olaf, Baxter, Patricia A., Kang, Hyoung Jin, Hassall, Timothy E., Han, Jung Woo, Hargrave, Darren, Franson, Andrea T., Yalon Oren, Michal, Toledano, Helen, Larouche, Valérie, Kline, Cassie, Abdelbaki, Mohamed S., Jabado, Nada, Gottardo, Nicholas G., Gerber, Nicolas U., Whipple, Nicholas S., Segal, Devorah, Chi, Susan N., Oren, Liat, Tan, Enrica E. K., Mueller, Sabine, Cornelio, Izzy, McLeod, Lisa, Zhao, Xin, Walter, Ashley, Da Costa, Daniel, Manley, Peter, Blackman, Samuel C., Packer, Roger J., and Nysom, Karsten

Published
2024
Full Text
View/download PDF

6. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study

Author

Ullrich, Nicole J, Prabhu, Sanjay P, Reddy, Alyssa T, Fisher, Michael J, Packer, Roger, Goldman, Stewart, Robison, Nathan J, Gutmann, David H, Viskochil, David H, Allen, Jeffrey C, Korf, Bruce, Cantor, Alan, Cutter, Gary, Thomas, Coretta, Perentesis, John P, Mizuno, Tomoyuki, Vinks, Alexander A, Manley, Peter E, Chi, Susan N, and Kieran, Mark W

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Brain Disorders, Orphan Drug, Neurofibromatosis, Pediatric, Biotechnology, Pediatric Research Initiative, Clinical Trials and Supportive Activities, Cancer, Brain Cancer, Rare Diseases, Neurosciences, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Antineoplastic Agents, Child, Everolimus, Glioma, Humans, Neurofibromatosis 1, Sirolimus, TOR Serine-Threonine Kinases, everolimus, low-grade glioma, neurofibromatosis, NF1, RAD001, PIK3K/mTOR pathway, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundActivation of the mammalian target of rapamycin (mTOR) pathway is observed in neurofibromatosis type 1 (NF1) associated low-grade gliomas (LGGs), but agents that inhibit this pathway, including mTOR inhibitors, have not been studied in this population. We evaluate the efficacy of the orally administered mTOR inhibitor everolimus for radiographically progressive NF1-associated pediatric LGGs.MethodsChildren with radiologic-progressive, NF1-associated LGG and prior treatment with a carboplatin-containing chemotherapy were prospectively enrolled on this phase II clinical trial to receive daily everolimus. Whole blood was analyzed for everolimus and markers of phosphatidylinositol-3 kinase (PI3K)/mTOR pathway inhibition. Serial MRIs were obtained during treatment. The primary endpoint was progression-free survival at 48 weeks.ResultsTwenty-three participants (median age, 9.4 y; range, 3.2-21.6 y) were enrolled. All participants were initially evaluable for response; 1 patient was removed from study after development of a malignant peripheral nerve sheath tumor. Fifteen of 22 participants (68%) demonstrated a response, defined as either shrinkage (1 complete response, 2 partial response) or arrest of tumor growth (12 stable disease). Of these, 10/15 remained free of progression (median follow-up, 33 mo). All remaining 22 participants were alive at completion of therapy. Treatment was well tolerated; no patient discontinued therapy due to toxicity. Pharmacokinetic parameters and pre-dose concentrations showed substantial between-subject variability. PI3K/mTOR pathway inhibition markers demonstrating blood mononuclear cell mTOR pathway inactivation was achieved in most participants.ConclusionIndividuals with recurrent/progressive NF1-associated LGG demonstrate significant disease stability/shrinkage during treatment with oral everolimus with a well-tolerated toxicity profile. Everolimus is well suited for future consideration as upfront or combination therapy in this patient population.

Published
2020

8. Structural variants shape driver combinations and outcomes in pediatric high-grade glioma

Author

Dubois, Frank P. B., Shapira, Ofer, Greenwald, Noah F., Zack, Travis, Wala, Jeremiah, Tsai, Jessica W., Crane, Alexander, Baguette, Audrey, Hadjadj, Djihad, Harutyunyan, Ashot S., Kumar, Kiran H., Blattner-Johnson, Mirjam, Vogelzang, Jayne, Sousa, Cecilia, Kang, Kyung Shin, Sinai, Claire, Wang, Dayle K., Khadka, Prasidda, Lewis, Kathleen, Nguyen, Lan, Malkin, Hayley, Ho, Patricia, O’Rourke, Ryan, Zhang, Shu, Gold, Rose, Deng, Davy, Serrano, Jonathan, Snuderl, Matija, Jones, Chris, Wright, Karen D., Chi, Susan N., Grill, Jacques, Kleinman, Claudia L., Goumnerova, Liliana C., Jabado, Nada, Jones, David T. W., Kieran, Mark W., Ligon, Keith L., Beroukhim, Rameen, and Bandopadhayay, Pratiti

Published
2022
Full Text
View/download PDF

10. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma.

Author

Gupta, Nalin, Goumnerova, Liliana C, Manley, Peter, Chi, Susan N, Neuberg, Donna, Puligandla, Maneka, Fangusaro, Jason, Goldman, Stewart, Tomita, Tadanori, Alden, Tord, DiPatri, Arthur, Rubin, Joshua B, Gauvain, Karen, Limbrick, David, Leonard, Jeffrey, Geyer, J Russel, Leary, Sarah, Browd, Samuel, Wang, Zhihong, Sood, Sandeep, Bendel, Anne, Nagib, Mahmoud, Gardner, Sharon, Karajannis, Matthias A, Harter, David, Ayyanar, Kanyalakshmi, Gump, William, Bowers, Daniel C, Weprin, Bradley, MacDonald, Tobey J, Aguilera, Dolly, Brahma, Barunashish, Robison, Nathan J, Kiehna, Erin, Krieger, Mark, Sandler, Eric, Aldana, Philipp, Khatib, Ziad, Ragheb, John, Bhatia, Sanjiv, Mueller, Sabine, Banerjee, Anu, Bredlau, Amy-Lee, Gururangan, Sri, Fuchs, Herbert, Cohen, Kenneth J, Jallo, George, Dorris, Kathleen, Handler, Michael, Comito, Melanie, Dias, Mark, Nazemi, Kellie, Baird, Lissa, Murray, Jeff, Lindeman, Neal, Hornick, Jason L, Malkin, Hayley, Sinai, Claire, Greenspan, Lianne, Wright, Karen D, Prados, Michael, Bandopadhayay, Pratiti, Ligon, Keith L, and Kieran, Mark W

Subjects
Brain Disorders, Genetics, Patient Safety, Neurosciences, Brain Cancer, Cancer, Clinical Research, Rare Diseases, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Adolescent, Biopsy, Brain Stem Neoplasms, Child, Child, Preschool, Feasibility Studies, Female, Follow-Up Studies, Glioma, Humans, Magnetic Resonance Imaging, Male, Morbidity, Prognosis, Prospective Studies, bevacizumab, DIPG, erlotinib, stereotactic biopsy, temozolomide, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Background:Diagnosis of diffuse intrinsic pontine glioma (DIPG) has relied on imaging studies, since the appearance is pathognomonic, and surgical risk was felt to be high and unlikely to affect therapy. The DIPG Biology and Treatment Study (DIPG-BATS) reported here incorporated a surgical biopsy at presentation and stratified subjects to receive FDA-approved agents chosen on the basis of specific biologic targets. Methods:Subjects were eligible for the trial if the clinical features and imaging appearance of a newly diagnosed tumor were consistent with a DIPG. Surgical biopsies were performed after enrollment and prior to definitive treatment. All subjects were treated with conventional external beam radiotherapy with bevacizumab, and then stratified to receive bevacizumab with erlotinib or temozolomide, both agents, or neither agent, based on O6-methylguanine-DNA methyltransferase status and epidermal growth factor receptor expression. Whole-genome sequencing and RNA sequencing were performed but not used for treatment assignment. Results:Fifty-three patients were enrolled at 23 institutions, and 50 underwent biopsy. The median age was 6.4 years, with 24 male and 29 female subjects. Surgical biopsies were performed with a specified technique and no deaths were attributed to the procedure. Two subjects experienced grade 3 toxicities during the procedure (apnea, n = 1; hypertension, n = 1). One subject experienced a neurologic deficit (left hemiparesis) that did not fully recover. Of the 50 tumors biopsied, 46 provided sufficient tissue to perform the study assays (92%, two-stage exact binomial 90% CI: 83%-97%). Conclusions:Surgical biopsy of DIPGs is technically feasible, associated with acceptable risks, and can provide biologic data that can inform treatment decisions.

Published
2018

12. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

Author

Kilburn, Lindsay B; https://orcid.org/0000-0003-1478-3619, Khuong-Quang, Dong-Anh; https://orcid.org/0000-0001-6305-7790, Hansford, Jordan R; https://orcid.org/0000-0001-7733-383X, Landi, Daniel, van der Lugt, Jasper; https://orcid.org/0000-0002-8186-338X, Leary, Sarah E S; https://orcid.org/0000-0003-0225-6184, Driever, Pablo Hernáiz; https://orcid.org/0000-0003-3135-3872, Bailey, Simon; https://orcid.org/0000-0003-4763-4329, Perreault, Sébastien, McCowage, Geoffrey, Waanders, Angela J, Ziegler, David S; https://orcid.org/0000-0001-7451-7916, Witt, Olaf, Baxter, Patricia A, Kang, Hyoung Jin; https://orcid.org/0000-0003-1009-6002, Hassall, Timothy E, Han, Jung Woo; https://orcid.org/0000-0001-8936-1205, Hargrave, Darren; https://orcid.org/0000-0001-8219-9807, Franson, Andrea T; https://orcid.org/0000-0002-5361-7683, Yalon Oren, Michal, Toledano, Helen, Larouche, Valérie; https://orcid.org/0000-0003-4082-7267, Kline, Cassie; https://orcid.org/0000-0001-7765-7690, Abdelbaki, Mohamed S, Jabado, Nada; https://orcid.org/0000-0003-2485-3692, Gottardo, Nicholas G; https://orcid.org/0000-0002-1082-6776, Gerber, Nicolas U; https://orcid.org/0000-0002-1783-631X, Whipple, Nicholas S, Segal, Devorah; https://orcid.org/0000-0002-9740-1286, Chi, Susan N, et al, Kilburn, Lindsay B; https://orcid.org/0000-0003-1478-3619, Khuong-Quang, Dong-Anh; https://orcid.org/0000-0001-6305-7790, Hansford, Jordan R; https://orcid.org/0000-0001-7733-383X, Landi, Daniel, van der Lugt, Jasper; https://orcid.org/0000-0002-8186-338X, Leary, Sarah E S; https://orcid.org/0000-0003-0225-6184, Driever, Pablo Hernáiz; https://orcid.org/0000-0003-3135-3872, Bailey, Simon; https://orcid.org/0000-0003-4763-4329, Perreault, Sébastien, McCowage, Geoffrey, Waanders, Angela J, Ziegler, David S; https://orcid.org/0000-0001-7451-7916, Witt, Olaf, Baxter, Patricia A, Kang, Hyoung Jin; https://orcid.org/0000-0003-1009-6002, Hassall, Timothy E, Han, Jung Woo; https://orcid.org/0000-0001-8936-1205, Hargrave, Darren; https://orcid.org/0000-0001-8219-9807, Franson, Andrea T; https://orcid.org/0000-0002-5361-7683, Yalon Oren, Michal, Toledano, Helen, Larouche, Valérie; https://orcid.org/0000-0003-4082-7267, Kline, Cassie; https://orcid.org/0000-0001-7765-7690, Abdelbaki, Mohamed S, Jabado, Nada; https://orcid.org/0000-0003-2485-3692, Gottardo, Nicholas G; https://orcid.org/0000-0002-1082-6776, Gerber, Nicolas U; https://orcid.org/0000-0002-1783-631X, Whipple, Nicholas S, Segal, Devorah; https://orcid.org/0000-0002-9740-1286, Chi, Susan N, and et al

Abstract

BRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade glioma (pLGG). Arm 1 (n = 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial investigated the efficacy of the oral, selective, central nervous system-penetrant, type II RAF inhibitor tovorafenib (420 mg m$^{-}$$^{2}$ once weekly; 600 mg maximum) in patients with BRAF-altered, relapsed/refractory pLGG. Arm 2 (n = 60) is an extension cohort, which provided treatment access for patients with RAF-altered pLGG after arm 1 closure. Based on independent review, according to Response Assessment in Neuro-Oncology High-Grade Glioma (RANO-HGG) criteria, the overall response rate (ORR) of 67% met the arm 1 prespecified primary endpoint; median duration of response (DOR) was 16.6 months; and median time to response (TTR) was 3.0 months (secondary endpoints). Other select arm 1 secondary endpoints included ORR, DOR and TTR as assessed by Response Assessment in Pediatric Neuro-Oncology Low-Grade Glioma (RAPNO) criteria and safety (assessed in all treated patients and the primary endpoint for arm 2, n = 137). The ORR according to RAPNO criteria (including minor responses) was 51%; median DOR was 13.8 months; and median TTR was 5.3 months. The most common treatment-related adverse events (TRAEs) were hair color changes (76%), elevated creatine phosphokinase (56%) and anemia (49%). Grade ≥3 TRAEs occurred in 42% of patients. Nine (7%) patients had TRAEs leading to discontinuation of tovorafenib. These data indicate that tovorafenib could be an effective therapy for BRAF-altered, relapsed/refractory pLGG. ClinicalTrials.gov registration: NCT04775485 .

Published
2024

13. Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer.

Author

Forrest, Suzanne J., Gupta, Hersh, Ward, Abigail, Li, Yvonne Y., Doan, Duong, Al-Ibraheemi, Alyaa, Alexandrescu, Sanda, Bandopadhayay, Pratiti, Shusterman, Suzanne, Mullen, Elizabeth A., Collins, Natalie B., Chi, Susan N., Wright, Karen D., Kumari, Priti, Mazor, Tali, Ligon, Keith L., Shivdasani, Priyanka, Manam, Monica, MacConaill, Laura E., and Ceca, Evelina

Subjects
CHILDHOOD cancer, NOSOLOGY, PEDIATRIC oncology, MEDICAL research, TUMOR classification, HOSPITAL care quality
Abstract

To inform clinical trial design and real-world precision pediatric oncology practice, we classified diagnoses, assessed the landscape of mutations, and identified genomic variants matching trials in a large unselected institutional cohort of solid tumors patients sequenced at Dana-Farber / Boston Children's Cancer and Blood Disorders Center. Tumors were sequenced with OncoPanel, a targeted next-generation DNA sequencing panel. Diagnoses were classified according to the International Classification of Diseases for Oncology (ICD-O-3.2). Over 6.5 years, 888 pediatric cancer patients with 95 distinct diagnoses had successful tumor sequencing. Overall, 33% (n = 289/888) of patients had at least 1 variant matching a precision oncology trial protocol, and 14% (41/289) were treated with molecularly targeted therapy. This study highlights opportunities to use genomic data from hospital-based sequencing performed either for research or clinical care to inform ongoing and future precision oncology clinical trials. Furthermore, the study results emphasize the importance of data sharing to define the genomic landscape and targeted treatment opportunities for the large group of rare pediatric cancers we encounter in clinical practice. Mutation profiling of pediatric cancers can help determine treatment options, however, large-scale datasets are rare. Here, the authors describe an institutional application of targeted sequencing to pediatric solid tumours, and identify potential therapeutic implications for identified mutations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma

Author

Mueller, Sabine, Taitt, Jared M., Villanueva-Meyer, Javier E., Bonner, Erin R., Nejo, Takahide, Lulla, Rishi R., Goldman, Stewart, Banerjee, Anu, Chi, Susan N., Whipple, Nicholas S., Crawford, John R., Gauvain, Karen, Nazemi, Kellie J., Watchmaker, Payal B., Almeida, Neil D., Okada, Kaori, Salazar, Andres M., Gilbert, Ryan D., Nazarian, Javad, Molinaro, Annette M., Butterfield, Lisa H., Prados, Michael D., and Okada, Hideho

Subjects
Cancer vaccines -- Physiological aspects -- Usage, Gliomas -- Drug therapy -- Development and progression -- Genetic aspects, Pediatric tumors -- Genetic aspects -- Drug therapy -- Development and progression, Gene mutation -- Health aspects, Histones -- Health aspects -- Genetic aspects, Health care industry
Abstract

BACKGROUND. Patients with diffuse midline gliomas (DMGs), including diffuse intrinsic pontine glioma (DIPG), have dismal outcomes. We previously described the H3.3K27M mutation as a shared neoantigen in [HLA-A.sup.*][02.01.sup.+], [H3.3K27M.sup.+] DMGs. Within the Pacific Pediatric Neuro-Oncology Consortium, we assessed the safety and efficacy of an H3.3K27M-targeted peptide vaccine. METHODS. Newly diagnosed patients, aged 3-21 years, with [HLA-A.sup.*][02.01.sup.+] and [H3.3K27M.sup.+] status were enrolled in stratum A (DIPG) or stratum B (nonpontine DMG). Vaccine was administered in combination with polyinosinic-polycytidylic acid-poly-Ilysine carboxymethylcellulose (poly-ICLC) every 3 weeks for 8 cycles, followed by once every 6 weeks. Immunomonitoring and imaging were performed every 3 months. Imaging was centrally reviewed. Immunological responses were assessed in PBMCs using mass cytometry. RESULTS. A total of 19 patients were enrolled in stratum A (median age, 11 years) and 10 in stratum B (median age, 13 years). There were no grade-4 treatment-related adverse events (TRAEs). Injection site reaction was the most commonly reported TRAE. Overall survival (OS) at 12 months was 40% (95% CI, 22%-73%) for patients in stratum A and 39% (95% CI, 16%-93%) for patients in stratum B. The median OS was 16.1 months for patients who had an expansion of H3.3K27M-reactive [CD8.sup.+] T cells compared with 9.8 months for their counterparts (P = 0.05). Patients with DIPG with below-median baseline levels of myeloid-derived suppressor cells had prolonged OS compared with their counterparts (P < 0.01). Immediate pretreatment dexamethasone administration was inversely associated with H3.3K27M-reactive [CD8.sup.+] T cell responses. CONCLUSION. Administration of the H3.3K27M-specific vaccine was well tolerated. Patients with H3.3K27M-specific [CD8.sup.+] immunological responses demonstrated prolonged OS compared with nonresponders. TRIAL REGISTRATION. ClinicalTrials.gov NCT02960230. FUNDING. The V Foundation, the Pacific Pediatric Neuro-Oncology Consortium Foundation, the Pediatric Brain Tumor Foundation, the Mithil Prasad Foundation, the MCJ Amelior Foundation, the Anne and Jason Farber Foundation, Will Power Research Fund Inc., the Isabella Kerr Molina Foundation, the Parker Institute for Cancer Immunotherapy, and the National Institute of Neurological Disorders and Stroke (NINDS), NIH (R35NS105068)., Introduction Diffuse midline gliomas (DMGs) are uniformly fatal pediatric brain cancers, and despite maximal therapy, survival outcomes remain dismal, with less than 10% of patients surviving beyond 2 years (1). [...]

Published
2020
Full Text
View/download PDF

16. Mechanisms and therapeutic implications of hypermutation in gliomas

Author

Touat, Mehdi, Li, Yvonne Y., Boynton, Adam N., Spurr, Liam F., Iorgulescu, J. Bryan, Bohrson, Craig L., Cortes-Ciriano, Isidro, Birzu, Cristina, Geduldig, Jack E., Pelton, Kristine, Lim-Fat, Mary Jane, Pal, Sangita, Ferrer-Luna, Ruben, Ramkissoon, Shakti H., Dubois, Frank, Bellamy, Charlotte, Currimjee, Naomi, Bonardi, Juliana, Qian, Kenin, Ho, Patricia, Malinowski, Seth, Taquet, Leon, Jones, Robert E., Shetty, Aniket, Chow, Kin-Hoe, Sharaf, Radwa, Pavlick, Dean, Albacker, Lee A., Younan, Nadia, Baldini, Capucine, Verreault, Maïté, Giry, Marine, Guillerm, Erell, Ammari, Samy, Beuvon, Frédéric, Mokhtari, Karima, Alentorn, Agusti, Dehais, Caroline, Houillier, Caroline, Laigle-Donadey, Florence, Psimaras, Dimitri, Lee, Eudocia Q., Nayak, Lakshmi, McFaline-Figueroa, J. Ricardo, Carpentier, Alexandre, Cornu, Philippe, Capelle, Laurent, Mathon, Bertrand, Barnholtz-Sloan, Jill S., Chakravarti, Arnab, Bi, Wenya Linda, Chiocca, E. Antonio, Fehnel, Katie Pricola, Alexandrescu, Sanda, Chi, Susan N., Haas-Kogan, Daphne, Batchelor, Tracy T., Frampton, Garrett M., Alexander, Brian M., Huang, Raymond Y., Ligon, Azra H., Coulet, Florence, Delattre, Jean-Yves, Hoang-Xuan, Khê, Meredith, David M., Santagata, Sandro, Duval, Alex, Sanson, Marc, Cherniack, Andrew D., Wen, Patrick Y., Reardon, David A., Marabelle, Aurélien, Park, Peter J., Idbaih, Ahmed, Beroukhim, Rameen, Bandopadhayay, Pratiti, Bielle, Franck, and Ligon, Keith L.

Published
2020
Full Text
View/download PDF

17. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

Author

Kilburn, Lindsay B., primary, Khuong-Quang, Dong-Anh, additional, Hansford, Jordan R., additional, Landi, Daniel, additional, van der Lugt, Jasper, additional, Leary, Sarah E. S., additional, Driever, Pablo Hernáiz, additional, Bailey, Simon, additional, Perreault, Sébastien, additional, McCowage, Geoffrey, additional, Waanders, Angela J., additional, Ziegler, David S., additional, Witt, Olaf, additional, Baxter, Patricia A., additional, Kang, Hyoung Jin, additional, Hassall, Timothy E., additional, Han, Jung Woo, additional, Hargrave, Darren, additional, Franson, Andrea T., additional, Yalon Oren, Michal, additional, Toledano, Helen, additional, Larouche, Valérie, additional, Kline, Cassie, additional, Abdelbaki, Mohamed S., additional, Jabado, Nada, additional, Gottardo, Nicholas G., additional, Gerber, Nicolas U., additional, Whipple, Nicholas S., additional, Segal, Devorah, additional, Chi, Susan N., additional, Oren, Liat, additional, Tan, Enrica E. K., additional, Mueller, Sabine, additional, Cornelio, Izzy, additional, McLeod, Lisa, additional, Zhao, Xin, additional, Walter, Ashley, additional, Da Costa, Daniel, additional, Manley, Peter, additional, Blackman, Samuel C., additional, Packer, Roger J., additional, and Nysom, Karsten, additional

Published
2023
Full Text
View/download PDF

20. Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.

Author

Peyrl, Andreas, Chocholous, Monika, Sabel, Magnus, Lassaletta, Alvaro, Sterba, Jaroslav, Leblond, Pierre, Nysom, Karsten, Torsvik, Ingrid, Chi, Susan N., Perwein, Thomas, Jones, Neil, Holm, Stefan, Nyman, Per, Mörse, Helena, Öberg, Anders, Weiler-Wichtl, Liesa, Leiss, Ulrike, Haberler, Christine, Schmook, Maresa T., and Mayr, Lisa

Published
2023
Full Text
View/download PDF

21. Tazemetostat for Tumors Harboring SMARCB1/SMARCA4 or EZH2 Alterations: Results from NCI-COG Pediatric MATCH APEC1621C

Author

Chi, Susan N, primary, Yi, Joanna S, additional, Williams, P Mickey, additional, Roy-Chowdhuri, Sinchita, additional, Patton, David R, additional, Coffey, Brent D, additional, Reid, Joel M, additional, Piao, Jin, additional, Saguilig, Lauren, additional, Alonzo, Todd A, additional, Berg, Stacey L, additional, Ramirez, Nilsa C, additional, Jaju, Alok, additional, Mhlanga, Joyce C, additional, Fox, Elizabeth, additional, Hawkins, Douglas S, additional, Mooney, Margaret M, additional, Takebe, Naoko, additional, Tricoli, James V, additional, Janeway, Katherine A, additional, Seibel, Nita L, additional, and Parsons, D Williams, additional

Published
2023
Full Text
View/download PDF

22. Supplementary Data from p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition

Author

Oppel, Felix, primary, Shao, Senyao, primary, Gendreizig, Sarah, primary, Zimmerman, Mark W., primary, Schürmann, Matthias, primary, Flavian, Viyof Ful, primary, Goon, Peter, primary, Chi, Susan N., primary, Aster, Jon C., primary, Sudhoff, Holger, primary, and Look, A. Thomas, primary

Published
2023
Full Text
View/download PDF

23. Data from p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition

Author

Oppel, Felix, primary, Shao, Senyao, primary, Gendreizig, Sarah, primary, Zimmerman, Mark W., primary, Schürmann, Matthias, primary, Flavian, Viyof Ful, primary, Goon, Peter, primary, Chi, Susan N., primary, Aster, Jon C., primary, Sudhoff, Holger, primary, and Look, A. Thomas, primary

Published
2023
Full Text
View/download PDF

24. Pub fees email yes from A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors

Author

Geoerger, Birgit, primary, Bourdeaut, Franck, primary, DuBois, Steven G., primary, Fischer, Matthias, primary, Geller, James I., primary, Gottardo, Nicholas G., primary, Marabelle, Aurélien, primary, Pearson, Andrew D.J., primary, Modak, Shakeel, primary, Cash, Thomas, primary, Robinson, Giles W., primary, Motta, Marlyane, primary, Matano, Alessandro, primary, Bhansali, Suraj G., primary, Dobson, Jason R., primary, Parasuraman, Sudha, primary, and Chi, Susan N., primary

Published
2023
Full Text
View/download PDF

25. Figure S1 from Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers

Author

Forrest, Suzanne J., primary, Al-Ibraheemi, Alyaa, primary, Doan, Duong, primary, Ward, Abigail, primary, Clinton, Catherine M., primary, Putra, Juan, primary, Pinches, R. Seth, primary, Kadoch, Cigall, primary, Chi, Susan N., primary, DuBois, Steven G., primary, Leavey, Patrick J., primary, LeBoeuf, Nicole R., primary, Mullen, Elizabeth, primary, Collins, Natalie, primary, Church, Alanna J., primary, and Janeway, Katherine A., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Table 1 and Supplementary Figure Legends from Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers

Author

Forrest, Suzanne J., primary, Al-Ibraheemi, Alyaa, primary, Doan, Duong, primary, Ward, Abigail, primary, Clinton, Catherine M., primary, Putra, Juan, primary, Pinches, R. Seth, primary, Kadoch, Cigall, primary, Chi, Susan N., primary, DuBois, Steven G., primary, Leavey, Patrick J., primary, LeBoeuf, Nicole R., primary, Mullen, Elizabeth, primary, Collins, Natalie, primary, Church, Alanna J., primary, and Janeway, Katherine A., primary

Published
2023
Full Text
View/download PDF

30. Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approach

Author

Fay-McClymont, Taryn B., Ploetz, Danielle M., Mabbott, Don, Walsh, Karin, Smith, Amy, Chi, Susan N., Wells, Elizabeth, Madden, Jennifer, Margol, Ashley, Finlay, Jonathan, Kieran, Mark W., Strother, Douglas, Dhall, Girish, Packer, Roger J., Foreman, Nicholas K., Bouffet, E., and Lafay-Cousin, Lucie

Published
2017
Full Text
View/download PDF

31. Pediatric Tumors

Author

Lee, Michelle A., Robison, Nathan J., Chi, Susan N., Gururangan, Sridharan, Kieran, Mark W., Norden, Andrew D., editor, Reardon, David A., editor, and Wen, Patrick C. Y., editor

Published
2011
Full Text
View/download PDF

32. p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition

Author

Oppel, Felix, primary, Shao, Senyao, additional, Gendreizig, Sarah, additional, Zimmerman, Mark W., additional, Schürmann, Matthias, additional, Flavian, Viyof Ful, additional, Goon, Peter, additional, Chi, Susan N., additional, Aster, Jon C., additional, Sudhoff, Holger, additional, and Look, A. Thomas, additional

Published
2022
Full Text
View/download PDF

34. Contributors

Author

Aaen, Gregory S., primary, Abend, Nicholas Scott, additional, Abou-Hamden, Amal, additional, Allen, Jeffrey C., additional, Amato, Anthony A., additional, Amlie-Lefond, Catherine, additional, Ashwal, Stephen, additional, Bailey, Russell C., additional, Bale, James F., additional, Banwell, Brenda, additional, Barañano, Kristin W., additional, Barkovich, A. James, additional, Barohn, Richard J., additional, Bartels, Ute K., additional, Bartnik-Olson, Brenda, additional, Barzilai, Ori, additional, Bassuk, Alexander, additional, Bearden, David R., additional, Ben-Sira, Liat, additional, Bernard, Timothy J., additional, Berry-Kravis, Elizabeth, additional, Beslow, Lauren A., additional, Biegel, Jaclyn A., additional, Billinghurst, Lori, additional, Birnbaum, Angela K., additional, Blackburn, Joanna S., additional, Bobowski, Nuala, additional, Boire, Adrienne, additional, Bönnemann, Carsten G., additional, Bonifacio, Sonia L., additional, Bonthius, Daniel J., additional, Borcherding, Breck, additional, Branchford, Brian R., additional, Brandsema, John, additional, Brennan, Kathryn M., additional, Brenton, J. Nicholas, additional, Brooks-Kayal, Amy R., additional, Brown, Lawrence W., additional, Buchalter, Jeffrey, additional, Camfield, Carol S., additional, Camfield, Peter R., additional, Campoy, Cristina, additional, Carpenter, Jessica L., additional, Chang, Taeun, additional, Chau, Vann, additional, Chi, Susan N., additional, Chiriboga, Claudia A., additional, Cho, Yoon-Jae, additional, Christian, Cindy W., additional, Chrestian, Nicholas, additional, Cilio, Maria Roberta, additional, Clark, Robin D., additional, Cohen, Bruce H., additional, Cohn, Ronald D., additional, Connolly, Anne M., additional, Constable, Todd, additional, Constantini, Shlomi, additional, Conway, Jeannine M., additional, Coulter, David L., additional, Cowan, Tina M., additional, Dale, Russell C., additional, Darbro, Benjamin, additional, Darras, Basil T., additional, Dastgir, Jahannaz, additional, De Meirleir, Linda, additional, De Vivo, Darryl C., additional, de Vries, Linda S., additional, Deisch, Jeremy K., additional, Deltenre, Paul, additional, Desai, Jay, additional, Descartes, Maria, additional, deVeber, Gabrielle, additional, Dhamne, Sameer C., additional, Diaz, Jullianne, additional, DiMauro, Salvatore, additional, Dobyns, William B., additional, Doherty, Dan, additional, Donner, Elizabeth J., additional, Dosenbach, Nico U.F., additional, Dowling, James J., additional, Drake, James M., additional, Ejerskov, Cecile, additional, Engel, Andrew G., additional, Enns, Gregory M., additional, Escolano-Margarit, María Victoria, additional, Etzion, Iris, additional, Fatemi, S. Ali, additional, Fehlings, Darcy L., additional, Feinberg, Michelle Lauren, additional, Ferriero, Donna M., additional, Filipek, Pauline A., additional, Finkel, Richard S., additional, Fisher, Paul G., additional, Flanigan, Kevin, additional, Foreman, Nicholas K., additional, Franco, Israel, additional, Frank, Yitzchak, additional, Fredrick, Douglas R., additional, Freeze, Hudson H., additional, Fuente-Mora, Cristina, additional, Furman, Joseph M., additional, Gallagher, Renata C., additional, Garel, Catherine, additional, Gertsch, Emily, additional, Gilbert, Donald L., additional, Gilles, Elizabeth E., additional, Giza, Christopher C., additional, Glaser, Carol A., additional, Glass, Hannah C., additional, Glauser, Tracy, additional, Glykys, Joseph, additional, Goldstein, Amy, additional, Gonorazky, Hernan Dario, additional, Gonzalez, Rodolfo, additional, Goodkin, Howard P., additional, Graham, John M., additional, Greninger, Alexander L., additional, Gronseth, Gary, additional, Gropman, Andrea L., additional, Grundy, Richard, additional, Guerrini, Renzo, additional, Gupta, Nalin, additional, Hahn, Jin S., additional, Hamblin, Milton H., additional, Hani, Abeer J., additional, Hanmantgad, Sharyu, additional, Harbert, Mary J., additional, Harini, Chellamani, additional, Harriott, Andrea M., additional, Heatwole, Chad, additional, Hershey, Andrew D., additional, Hirtz, Deborah G., additional, Holmes, Gregory L., additional, Holshouser, Barbara A., additional, Hurwitz, Kathleen A., additional, Hwang, Eugene, additional, Ichord, Rebecca N., additional, Jafar-Nejad, Paymaan, additional, Jain, Sejal V., additional, Jordan, Lori, additional, Kabbouche, Marielle A., additional, Kacperski, Joanne, additional, Kang, Peter B., additional, Kariannis, Matthias A., additional, Kaufmann, Horacio, additional, Kaye, Harper L., additional, Keating, Robert, additional, Kennedy, Colin R., additional, Khakoo, Yasmin, additional, Kirton, Adam, additional, Kissel, John T., additional, Knupp, Kelly G., additional, Korf, Bruce R., additional, Kossoff, Eric H., additional, Kothare, Sanjeev V., additional, Kupfer, Oren, additional, LaFrance, W. Curt, additional, Latal, Beatrice, additional, Leber, Steven M., additional, Lee, Jean-Pyo, additional, Leppik, Ilo E., additional, Lerman-Sagie, Tally, additional, Lerner, Jason T., additional, Leventer, Richard J., additional, Licht, Daniel J., additional, Lichter-Konecki, Uta, additional, Lidar, Zvi, additional, Liem, Djin Gie, additional, Loddenkemper, Tobias, additional, Long, Roger K., additional, Luc, Quyen N., additional, Mackay, Mark, additional, Majnemer, Annette, additional, Makhani, Naila, additional, Malinger, Gustavo, additional, Mandelbaum, David E., additional, Maricich, Stephen M., additional, Maski, Kiran P., additional, Mathur, Mudit, additional, Matthews, Dennis J., additional, McMahon, Kelly, additional, DeMara-Hoth, Megan B., additional, Mendelsohn, Bryce, additional, Mennella, Julie A., additional, Ment, Laura R., additional, Mercuri, Eugenio, additional, Michelson, David J., additional, Mikati, Mohamad A., additional, Mikhail, Fady M., additional, Miller, Steven Paul, additional, Milunsky, Jeff M., additional, Mink, Jonathan W., additional, Mirzaa, Ghayda M., additional, Mitchell, Wendy G., additional, Mohan, Michael A., additional, Mohassel, Payam, additional, Moharir, Mahendranath, additional, Monani, Umrao R., additional, Monje Deisseroth, Michelle, additional, Moodley, Manikum, additional, Mower, Andrew, additional, Moxley, Richard T., additional, Mueller, Sabine, additional, Muotri, Alysson R., additional, Nagamani, Sandesh C.S., additional, Narayanan, Mohan J., additional, Narayanan, Vinodh, additional, Nass, Ruth D., additional, Neul, Jeffrey L., additional, Nevo, Yoram, additional, Ng, Bobby G., additional, Nickels, Katherine C., additional, Nimmo, Graeme A.M., additional, Noetzel, Michael J., additional, Norcliffe-Kaufmann, Lucy, additional, Nordli, Douglas R., additional, Nowak-Göttl, Ulrike, additional, O'Brien, Hope L., additional, Oleszek, Joyce, additional, Oskoui, Maryam, additional, Paciorkowski, Alex R., additional, Packer, Roger J., additional, Packman, Seymour, additional, Palma, Jose-Alberto, additional, Pardo, Andrea C., additional, Parsons, Julie A., additional, Partridge, John Colin, additional, Pastores, Gregory M., additional, Patterson, Marc C., additional, Pearce, William J., additional, Pearl, Phillip L., additional, Penner, Melanie, additional, Percival, Leila, additional, Pereira, Marcia, additional, Pfister, Stefan M., additional, Phillips, John, additional, Plecko, Barbara, additional, Plioplys, Sigita, additional, Poduri, Annapurna, additional, Poisson, Sharon, additional, Pomeroy, Scott L., additional, Poretti, Andrea, additional, Powers, Scott W., additional, Pranzatelli, Michael R., additional, Przekop, Allison, additional, Rabie, Malcolm, additional, Rangasamy, Sampathkumar, additional, Raymond, Gerald V., additional, Reddy, Alyssa T., additional, Rendleman, Rebecca L., additional, Rho, Jong M., additional, Rodan, Lance H., additional, Roddy, Sarah M., additional, Rogers, Elizabeth E., additional, Rosenthal, Stephen M., additional, Rosman, N. Paul, additional, Ross, M. Elizabeth, additional, Rotenberg, Alexander, additional, Rust, Robert S., additional, Sanchez, Cheryl P., additional, Sanchez, Pedro, additional, Sánchez Fernández, Iván, additional, Sands, Tristan T., additional, Sanger, Terence D., additional, Sannagowdara, Kumar, additional, Scheinost, Dustin, additional, Scher, Mark S., additional, Schor, Nina F., additional, Schrauwen, Isabelle, additional, Segal, Michael M., additional, Seinfeld, Syndi, additional, Selcen, Duygu, additional, Seltzer, Laurie E., additional, Semrud-Clikeman, Margaret, additional, Shaw, Dennis W., additional, Shaywitz, Bennett A., additional, Shaywitz, Sally E., additional, Shellhaas, Renée A., additional, Sherr, Elliott H., additional, Sheth, Rita D., additional, Shevell, Michael I., additional, Shinnar, Shlomo, additional, Shofty, Ben, additional, Shu, Stanford K., additional, Shy, Michael E., additional, Silveira Moriyama, Laura, additional, Silvestri, Nicholas J., additional, Sims, Katherine B., additional, Singer, Harvey S., additional, Singhal, Nilika Shah, additional, Smith, Craig M., additional, Smith, Edward, additional, Smith, Stephen A., additional, Snyder, Evan Y., additional, Soul, Janet, additional, Spalink, Christy L., additional, Spencer, Karen A., additional, Stafstrom, Carl E., additional, Steinfeld, Robert, additional, Strober, Jonathan B., additional, Sullivan, Joseph, additional, Swaiman, Kenneth F., additional, Swoboda, Kathryn J., additional, Tate, Elizabeth D., additional, Tatum, William O., additional, Tein, Ingrid, additional, Tekulve, Kristyn, additional, Tenney, Jeffrey R., additional, Thiele, Elizabeth A., additional, Thompson-Stone, Robert, additional, Tochen, Laura, additional, Tormoehlen, Laura M., additional, Tran, Lily, additional, Trauner, Doris A., additional, Turnacioglu, Sinan O., additional, Ullrich, Nicole J., additional, Urion, David K., additional, Van Camp, Guy, additional, Van Hirtum-Das, Michèle, additional, van Karnebeek, Clara D.M., additional, Van Maldergem, Lionel, additional, Vanderver, Adeline, additional, Vitanza, Nicholas A., additional, von Rhein, Michael, additional, von Scheven, Emily, additional, Wagner, Ann, additional, Wainwright, Mark S., additional, Walker, Melissa A., additional, Walkup, John T., additional, Walsh, Laurence, additional, Walters-Sen, Lauren C., additional, Wang, Raymond Y., additional, Warner, Thomas T., additional, Whelan, Harry T., additional, Weinberg, Geoffrey A., additional, Wells, Elizabeth M., additional, Wheless, James W., additional, Wirrell, Elaine C., additional, Wisoff, Jeffrey H., additional, Wolf, Nicole I., additional, Wolfe, Gil I., additional, Wright, F. Virginia, additional, Wycliffe, Nathaniel D., additional, Yang, Michele L., additional, Yuskaitis, Christopher J., additional, Zoghbi, Huda Y., additional, and Zupanc, Mary L., additional

Published
2017
Full Text
View/download PDF

36. Myxopapillary ependymomas in children: imaging, treatment and outcomes

Author

Bandopadhayay, Pratiti, Silvera, V. Michelle, Ciarlini, Pedro D. S. C., Malkin, Hayley, Bi, Wenya Linda, Bergthold, Guillaume, Faisal, Ahmed M., Ullrich, Nicole J., Marcus, Karen, Scott, R. Michael, Beroukhim, Rameen, Manley, Peter E., Chi, Susan N., Ligon, Keith L., Goumnerova, Liliana C., and Kieran, Mark W.

Published
2016
Full Text
View/download PDF

37. Abstract 3890: Sequencing of 888 pediatric solid tumors informs precision oncology trial design and data sharing initiatives in pediatric cancer

Author

Forrest, Suzanne J., primary, Gupta, Hersh, additional, Ward, Abigail, additional, Li, Yvonne, additional, Doan, Duong, additional, Al-Ibraheemi, Alyaa, additional, Alexandrescu, Sanda, additional, Bandopadhayay, Pratiti, additional, Shusterman, Suzanne, additional, Mullen, Elizabeth A., additional, Collins, Natalie, additional, Chi, Susan N., additional, Wright, Karen D., additional, Kumari, Priti, additional, Mazor, Tali, additional, Ligon, Keith L., additional, Shivdasani, Priyanka, additional, Davineni, Phani, additional, Manam, Monica, additional, Schilsky, Richard L., additional, Bruinooge, Suanna S., additional, Auvil, Jaime M. Guidry, additional, Cerami, Ethan, additional, Rollins, Barrett J., additional, Meyerson, Matthew L., additional, Lindeman, Neal I., additional, MacConaill, Laura, additional, Johnson, Bruce E., additional, Cherniack, Andrew D., additional, Church, Alanna J., additional, and Janeway, Katherine A., additional

Published
2022
Full Text
View/download PDF

38. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma

Author

Mueller, Sabine, primary, Taitt, Jared M., additional, Villanueva-Meyer, Javier E., additional, Bonner, Erin R., additional, Nejo, Takahide, additional, Lulla, Rishi R., additional, Goldman, Stewart, additional, Banerjee, Anu, additional, Chi, Susan N., additional, Whipple, Nicholas S., additional, Crawford, John R., additional, Gauvain, Karen, additional, Nazemi, Kellie J., additional, Watchmaker, Payal B., additional, Almeida, Neil D., additional, Okada, Kaori, additional, Salazar, Andres M., additional, Gilbert, Ryan D., additional, Nazarian, Javad, additional, Molinaro, Annette M., additional, Butterfield, Lisa H., additional, Prados, Michael D., additional, and Okada, Hideho, additional

Published
2022
Full Text
View/download PDF

39. Update on phase 1 study of tazemetostat, an enhancer of zeste homolog 2 inhibitor, in pediatric patients with relapsed or refractory integrase interactor 1–negative tumors.

Author

Chi, Susan N., primary, Bourdeaut, Franck, additional, Casanova, Michela, additional, Kilburn, Lindsay Baker, additional, Hargrave, Darren R., additional, McCowage, Geoffrey Brian, additional, Pinto, Navin R., additional, Yang, Jay, additional, Chadha, Raminder, additional, Kahali, Bhaskar, additional, Tapia, Coya, additional, and Nysom, Karsten, additional

Published
2022
Full Text
View/download PDF

40. Tazemetostat in patients with tumors with alterations in EZH2 or the SWI/SNF complex: Results from NCI-COG Pediatric MATCH trial Arm C (APEC1621C).

Author

Chi, Susan N., primary, Yi, Joanna S., additional, Williams, P. Mickey, additional, Roy-Chowdhuri, Sinchita, additional, Patton, David R., additional, Coffey, Brent, additional, Reid, Joel M., additional, Piao, Jin, additional, Saguilig, Lauren, additional, Alonzo, Todd Allen, additional, Berg, Stacey L., additional, Mhlanga, Joyce, additional, Fox, Elizabeth, additional, Hawkins, Douglas S., additional, Mooney, Margaret M., additional, Takebe, Naoko, additional, Tricoli, James V., additional, Janeway, Katherine A., additional, Seibel, Nita, additional, and Parsons, Donald Williams, additional

Published
2022
Full Text
View/download PDF

41. HGG-34. Upfront Molecular Targeted Therapy for the Treatment of BRAF-mutant Pediatric High-Grade Glioma

Author

Rosenberg, Tom, primary, Yeo, Kee Kiat, additional, Mauguen, Audrey, additional, Alexandrescu, Sanda, additional, Prabhu, Sanjay P, additional, Tsai, Jessica W, additional, Malinowski, Seth, additional, Joshirao, Mrinal, additional, Parikh, Karishma, additional, Sait, Sameer Farouk, additional, Rosenblum, Marc K, additional, Benhamida, Jamal K, additional, Michaiel, George, additional, Tran, Hung N, additional, Dahiya, Sonika, additional, Kachurak, Kara, additional, Friedman, Gregory K, additional, Krystal, JulieI, additional, Huang, Michael A, additional, Margol, Ashley S, additional, Wright, Karen D, additional, Aguilera, Dolly, additional, MacDonald, Tobey J, additional, Chi, Susan N, additional, and Karajannis, Matthias A, additional

Published
2022
Full Text
View/download PDF

42. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma

Author

Mueller, Sabine, Taitt, Jared M, Villanueva-Meyer, Javier E, Bonner, Erin R, Nejo, Takahide, Lulla, Rishi R, Goldman, Stewart, Banerjee, Anu, Chi, Susan N, Whipple, Nicholas S, Crawford, John R, Gauvain, Karen, Nazemi, Kellie J, Watchmaker, Payal B, Almeida, Neil D, Okada, Kaori, Salazar, Andres M, Gilbert, Ryan D, Nazarian, Javad, Molinaro, Annette M, Butterfield, Lisa H, Prados, Michael D, Okada, Hideho, Mueller, Sabine, Taitt, Jared M, Villanueva-Meyer, Javier E, Bonner, Erin R, Nejo, Takahide, Lulla, Rishi R, Goldman, Stewart, Banerjee, Anu, Chi, Susan N, Whipple, Nicholas S, Crawford, John R, Gauvain, Karen, Nazemi, Kellie J, Watchmaker, Payal B, Almeida, Neil D, Okada, Kaori, Salazar, Andres M, Gilbert, Ryan D, Nazarian, Javad, Molinaro, Annette M, Butterfield, Lisa H, Prados, Michael D, and Okada, Hideho

Published
2022

44. Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma

Author

Rosenberg, Tom, primary, Yeo, Kee Kiat, additional, Mauguen, Audrey, additional, Alexandrescu, Sanda, additional, Prabhu, Sanjay P, additional, Tsai, Jessica W, additional, Malinowski, Seth, additional, Joshirao, Mrinal, additional, Parikh, Karishma, additional, Farouk Sait, Sameer, additional, Rosenblum, Marc K, additional, Benhamida, Jamal K, additional, Michaiel, George, additional, Tran, Hung N, additional, Dahiya, Sonika, additional, Kachurak, Kara, additional, Friedman, Gregory K, additional, Krystal, Julie I, additional, Huang, Michael A, additional, Margol, Ashley S, additional, Wright, Karen D, additional, Aguilera, Dolly, additional, MacDonald, Tobey J, additional, Chi, Susan N, additional, and Karajannis, Matthias A, additional

Published
2022
Full Text
View/download PDF

45. Pearls & Oy-sters: Pivoting Treatment Regimens of Pediatric Atypical Teratoid Rhabdoid Tumors to Optimize Care in Adult ATRT: A Case Report

Author

Rao, Rohan, primary, Koehler, Abigail, additional, Rothman, Yehudit, additional, Turner, Brandi, additional, Denlinger, Jamie, additional, Erickson, Melissa, additional, Hagen, Matthew, additional, Braverman, Timothy S., additional, Mahammedi, Abdelkader, additional, Golnik, Karl, additional, Zuccarello, Mario, additional, Gozal, Yair M., additional, Broun, E. Randolph, additional, Chi, Susan N., additional, and Sengupta, Soma, additional

Published
2022
Full Text
View/download PDF

46. List of Contributors

Author

Ankenbrandt, William, primary, Arrillaga-Romany, Isabel, additional, Atsina, K.K., additional, Badve, Chaitra A., additional, Baehring, J.M., additional, Baldassarre, Randall Lawrence, additional, Bi, Wenya Linda, additional, Black, Peter M., additional, Boehm, Ingrid B., additional, Bolles, Genevieve, additional, Bourekas, Eric C., additional, Brennan, Nicole Petrovich, additional, Bussiere, Marc, additional, Cha, Soonmee, additional, Chakravarti, Arnab, additional, Chamberlain, Marc C., additional, Chang, Susan M., additional, Chapman, Paul H., additional, Chen, Clark C., additional, Chi, Susan N., additional, Chourmouzi, D., additional, Christoforidis, Gregory A., additional, Chukwueke, Ugonma, additional, Clarke, Jennifer L., additional, Collins, John M., additional, da Cruz, L. Celso Hygino, additional, Dolati, Parviz, additional, Drevelegas, A., additional, Drevelegas, K., additional, Eisele, Sylvia, additional, Ellika, Shehanaz, additional, Ferrante, Mark A., additional, Ferraro, Nicholas C., additional, Fisicaro, Ryan, additional, Golby, Alexandra J., additional, Goulart, Carlos R., additional, Guiou, Michael, additional, Gupta, Nilendu, additional, Hata, Nobuhiko, additional, Hearshen, David, additional, Henson, John W., additional, Heverhagen, Johannes T., additional, Holodny, Andrei, additional, Hughes, Tudor Hesketh, additional, Ichise, Masanori, additional, Ivan, Michael E., additional, Jain, Rajan, additional, Jolesz, Ferenc A., additional, Jordan, Justin T., additional, Daniel, Kacher, additional, Kangarlu, Alayar, additional, Kardan, Arash, additional, Kijewski, Marie Foley, additional, Kimura, Margareth, additional, Kissel, John T., additional, Komotar, Ricardo J., additional, Krol, George, additional, Kumthekar, Priya, additional, Lantos, Joshua, additional, Le Rhun, Emilie, additional, Lev, Michael H., additional, Loeffler, Jay S., additional, Maier, Stephan E., additional, Majithia, Lonika, additional, Mattei, Tobias A., additional, McCullough, Brendan J., additional, Mendel, Ehud, additional, Mikkelsen, Tom, additional, Miloushev, Vesselin Z., additional, Miranda, Pedro C., additional, Monje, Michelle, additional, Nagpal, Prashant, additional, Nakanote, Ken Alexander, additional, Newton, Herbert B., additional, Nine, Erik B., additional, Oberheim Bush, Nancy Ann, additional, Olubiyi, Olutayo, additional, Omay, S.B., additional, Paleologos, Nina, additional, Papanicolaou, N., additional, Patel, Kunal S., additional, Poussaint, Tina Young, additional, Prabhu, Sanjay P., additional, Qu, Jinrong, additional, Raizer, Jeffrey J., additional, Reddy, Haricharan, additional, Rizvi, Tanvir, additional, Rogers, Lisa R., additional, Satter, Martin, additional, Sattur, Mithun G., additional, Schiff, David, additional, Schmainda, Kathleen, additional, Schweitzer, Andrew D., additional, Silvera, Victoria Michelle, additional, Slone, H. Wayne, additional, Snyder, James, additional, Sodickson, Aaron D., additional, Sodickson, Daniel K., additional, Solnes, Lilja Bjork, additional, Spampinato, Maria Vittoria, additional, Sun, Yanping, additional, Taillibert, Sophie, additional, Talos, Ion-Florin, additional, Tharin, Suzanne, additional, Vagal, Achala, additional, Vernino, Steven, additional, Vogelbaum, Michael A., additional, Vossough, Arastoo, additional, Walston, Steve, additional, Warfield, Simon K., additional, Weicker, Michael A., additional, Welling, D. Bradley, additional, Wenger, Cornelia, additional, Wen, Patrick Y., additional, Wintermark, Max, additional, Wong, Eric T., additional, Xinou, E., additional, Yang, Edward, additional, Yeh, Randy, additional, Young, Geoffrey S., additional, Young, Robert J., additional, and Zukas, Alicia M., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results